查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424394

1型多腺体自体自体免疫症候群的全球市场：依诊断、治疗、剂型、给药途径、发病年龄、分销管道和地区

Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, By Treatment, By Dosage Form, By Route of Administration, By Age of Onset, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 172 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球多腺体自体自体免疫症候群 1 型市场规模预计将从 2023 年的 2.57 亿美元增至 2030 年的 3.179 亿美元，预测期内复合年增长率为 3.1%。

报告范围 报告详情
基准年 2022年 2023/2024年市场规模 2.57 亿美元
实际资料 2018-2021 预测期 2023-2030
预测期间 2023/2024 至 2030/2031 年复合年增长率： 3.10% 2030/2031 年预测值 3.179 亿美元
图 1. 1 型多腺体自体免疫症候群的全球市场占有率(%)，按地区划分，2023 年
全球自体免疫多腺体症候群 1 型市场-IMG1

多腺体自体自体免疫症候群1型（APS1），也称为自体自体免疫多内分泌疾病-安迪氏症-外胚层营养不良症（APECED），是一种多内分泌腺疾病，包括肾上腺、副甲状腺、性腺和其他组织，是一种罕见的罕见疾病。由自体免疫破坏引起的多系统疾病。 APS1 是 AIRE 基因（自体免疫调节因子）突变的结果，该基因控制组织特异性基因的表达并促进中枢耐受诱导。 AIRE 功能的丧失会导致免疫耐受性失败并引发多器官自体自体免疫攻击。 APS1 的常见临床特征包括副甲状腺功能低下、原发性甲状旁腺功能低下症、慢性皮肤黏膜念珠菌症病和性腺功能不全。多系统受累的早期发病和严重程度需要对 APS1 患者进行终身管理和监测。

市场动态：

由于全球 APS1 盛行率不断上升，预计全球 1 型多腺体自体自体免疫症候群市场将呈现利润丰厚的成长机会。针对高风险族群的基因筛检计画正在提高早期诊断率。越来越多的研究阐明免疫疾病机制和开发新型耐受诱导疗法也正在推动市场成长。然而，缺乏核准的标靶药物和有限的治疗选择继续限制市场。同时，提高人们对罕见疾病的认识并专注于开发新生技药品的努力有可能创造有吸引力的机会。作为一种罕见疾病，APS-1 可能会受益于孤儿药指定和鼓励研究和开发的激励措施。正在进行的研究旨在提高我们对潜在机制的理解，并实现更有针对性和有效的治疗。然而，患者数量有限给大规模临床试验和药物开发带来了挑战。

製药公司、研究机构和患者支持组织之间的合作对于推进 APS-1 的研究和改善受这种复杂自体自体免疫综合征影响的人们的生活品质至关重要。市场动态受到医学进步和支持罕见疾病治疗的监管环境的影响。

本研究的主要特点

本报告对全球多腺体自体自体免疫症候群1型市场进行了详细分析，并介绍了以2022年为基准年的预测期（2023-2030）的市场规模和復合年增长率。

它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。

根据公司亮点、产品系列、主要成就、财务绩效和策略等参数，对全球 1 型自体免疫腺体自体免疫症候群市场的主要企业进行了分析。

该报告的见解将帮助行销人员和经营团队高层就未来的产品发布、升级、市场扩张和行销策略负责人明智的决策。

本研究报告针对该产业的各个相关人员，如投资者、供应商、产品製造商、经销商、新参与企业和财务分析师。

透过用于分析全球多腺体自体自体免疫症候群 1 型市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 监管场景
  • 服务交付组合
  • PEST分析
  • 波特的分析
  • 併购场景
  • 管道分析

第四章全球多腺体自体自体免疫症候群 1 型市场 –冠状病毒(COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第 5 章 2018-2030 年全球多腺体自体自体免疫症候群 1 型市场（依诊断）

  • 血清自体自体免疫筛检
  • 终末器官功能检测
  • 验血

第 6 章 2018-2030 年全球多腺体自体自体免疫症候群 1 型市场（依治疗）

  • 药品
  • 抗真菌剂
  • Fluconazole
  • Itraconazole
  • 骨化三醇
  • 皮质类固醇
  • 其他（荷尔蒙替代疗法等）

第7章全球多腺体自体自体免疫症候群1型市场，按剂型，2018-2030

  • 锭剂
  • 胶囊
  • 其他的

第 8 章全球多腺体自体自体免疫症候群 1 型市场，依给药途径，2018-2030 年

  • 口服
  • 其他的

第 9 章 2018-2030 年全球多腺体自体自体免疫症候群 1 型市场（依发病年龄）

  • 孩子
  • 成人
  • 青春期

第10章全球多腺体自体免疫症候群1型市场，依通路，2018-2030年

  • 医院药房
  • 零售药房
  • 网路药房

第十一章全球多腺体自体免疫综合症 1 型市场，按地区，2018-2030

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第十二章竞争形势

  • Pfizer Inc.
    • Product & Service Portfolio
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S

第13章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6538

The global autoimmune polyglandular syndrome type 1 market size is expected to reach US$ 317.9 Mn by 2030, from US$ 257 Mn in 2023, exhibiting a CAGR of 3.1% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 257 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.10% 2030/2031 Value Projection: US$ 317.9 Mn
Figure 1. Global Autoimmune Polyglandular Syndrome Type 1 Market Share (%), By Region, 2023
Global Autoimmune Polyglandular Syndrome Type 1 Market - IMG1

Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare multisystem disorder caused by the autoimmune destruction of several endocrine glands like the adrenals, parathyroid glands, gonads, and other tissues. APS1 results from mutations in the AIRE gene (autoimmune regulator), which regulates the expression of tissue-specific genes and promotes central tolerance induction. Loss of function of AIRE leads to failures in immune tolerance, leading to autoimmune attacks on multiple organs. Common clinical features of APS1 include hypoparathyroidism, primary adrenal insufficiency, chronic mucocutaneous candidiasis, and gonadal failure. Early onset and severity of multiorgan involvement require lifelong management and monitoring of APS1 patients.

Market Dynamics:

The global autoimmune polyglandular syndrome type 1 market is projected to witness lucrative growth opportunities owing to rising APS1 disease prevalence worldwide. Genetic screening programs for high-risk ethnic populations are driving the early diagnosis rate. Increasing research into understanding immunological disease mechanisms and developing novel tolerance-inducing therapies is also fueling market growth. However, a lack of approved targeted drugs and limited treatment options continue to hamper the market. Meanwhile, initiatives to enhance rare disease awareness and focus on developing new biologics hold potential to create attractive opportunities. As a rare disease, APS-1 may benefit from orphan drug designations and incentives to encourage research and development. Ongoing research aims to deepen our understanding of the underlying mechanisms, allowing for more targeted and effective treatments. However, the limited patient population poses challenges for large-scale clinical trials and drug development.

Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups is crucial for advancing APS-1 research and improving the quality of life for individuals affected by this complex autoimmune syndrome. The market dynamics are influenced by both medical advancements and the regulatory landscape supporting rare disease treatments.

Key features of the study:

This report provides in-depth analysis of the global autoimmune polyglandular syndrome type 1 market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autoimmune polyglandular syndrome type 1 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autoimmune polyglandular syndrome type 1 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autoimmune polyglandular syndrome type 1 market

Detailed Segmentation:

  • By Diagnosis
    • Serum Autoimmune Screen
    • End-organ Function Tests
    • Blood Tests
  • By Treatment
    • Medication
    • Antifungal Agents
    • Fluconazole
    • Itraconazole
    • Calcitriol
    • Corticosteroids
    • Others (Hormone Replacement Therapy, etc.)
  • By Dosage Form
    • Tablet
    • Capsule
    • Others
  • By Route of Administration
    • Oral
    • Others
  • By Age of Onset
    • Childhood
    • Adult
    • Adolescent
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Key Players:
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F.Hoffmann-La Roche Ltd.
    • Zydus Cadila
    • Lupin
    • Amneal Pharmaceuticals LLC.
    • Cipla Inc.
    • Aurobindo Pharma
    • Glenmark Pharmaceuticals Limited
    • Eli Lilly and Company
    • Sun Pharmaceutical Industries Ltd.
    • Allergan
    • Bristol-Myers Squibb Company
    • Takeda Pharmaceutical Company Limited
    • Abbott
    • LEO Pharma A/S

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel
    • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increased incidence of autoimmune disorders
    • Growing Genetic Research Insights
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Service offering Portfolio
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Pipeline Analysis

4. Global Autoimmune Polyglandular Syndrome Type 1 Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Serum Autoimmune Screen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • End-organ Function Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Blood Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Antifungal Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Fluconazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Itraconazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Calcitriol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Hormone Replacement Therapy, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Tablet
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Capsule
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

8. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

9. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Childhood
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Adolescent
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

10. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

11. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product & Service Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S
  • Analyst Views

13. Section

  • Research Methodology
  • About us